Investment Bank Reiterates 'Buy' Rating On Pharmaceutical Company

In today's volatile market, discerning investors are constantly on the lookout for promising ventures that offer a strong return potential. One such opportunity that has piqued interest is Iterum Therapeutics (NASDAQ: $ITRM), a clinical-stage pharmaceutical company focused on developing anti-infectives to combat multi-drug resistant pathogens. Recently, HC Wainwright & Co., a renowned investment bank, has reiterated a 'Buy' rating on Iterum, maintaining a robust $6 price target. $Iterum Therapeutics(ITRM.US)$